Joint Statement on "Three Priorities for Promptly Increasing Access to COVID-19 Vaccine
February 28, 2022
Japan Pharmaceutical Manufacturers Association
The Japan Pharmaceutical Manufacturers Association (Chairman: Yasushi Okada, hereinafter referred to as "JPMA") is pleased to announce the release of a statement on the "Three Priorities for Promptly Increasing Access to COVID-19 Vaccine" developed by national pharmaceutical organizations.
The original text of this joint statement can be found here.
Three priorities to urgently increase access to COVID-19 vaccines
Please refer to the attached document* for a Japanese translation of the joint statement.
The attached document is a translation of a press release issued on February 25, 2022, by the pharmaceutical associations of each country and is provided for your reference. The official language is English, and English takes precedence in content and interpretation.
The Pharmaceutical Manufacturers Association of Japan (PMAJ) is committed to working with a wide range of stakeholders to help achieve improvements in vaccine equity.
Appendix.
For inquiries, please contact
Public Relations Department, Japan Pharmaceutical Manufacturers Association
- Phone.
- 03-3241-0374